Table 2.
Comparison of clinical features in patients with progression patterns information.
| Clinical Features | Training group (n = 195) | Validation group (n = 60) | p value |
|---|---|---|---|
| Age | |||
| Median (range) | 61 (26–81) | 59 (35–84) | t-test p=0.777 |
| Gender (n%) | |||
| Male | 77 (39.5) | 20 (33.3) | Pearson χ2 test p=0.737 |
| Female | 118 (60.5) | 40 (66.7) | |
| Smoking history | |||
| Yes | 156 (80.0) | 49 (81.7) | Pearson χ2 test p=0.776 |
| No | 39 (20.0) | 11 (18.3) | |
| PFS (months) | |||
| Median | 8 | 11 | Log-rank test p=0.131 |
| T Stage | |||
| T1 | 38 (19.5%) | 11 (18.3%) | Mann-Whitney test p=0.865 |
| T2 | 41 (21.0%) | 12 (20%) | |
| T3 | 16 (8.2%) | 6 (10.0%) | |
| T4 | 100 (51.3%) | 31 (51.7%) | |
| Metastasis pattern at initial diagnosis | |||
| Oligometastasis | 26 (13.3%) | 13 (21.7%) | Pearson χ2 test p=0.117 |
| Systematic metastasis | 169 (86.7) | 47 (78.3) | |
| Progression pattern | |||
| Oligoprogression | 77 (39.5) | 25 (41.7) | Pearson χ2 test p=0.763 |
| Systematic progression | 118 (60.5) | 35 (58.3) | |
| EGFR mutation site | |||
| 19del | 105 (53.8%) | 33 (55%) | Pearson χ2 test p=0.756 |
| 21L858R | 83 (42.6%) | 26 (43.3%) | |
| Double site | 7 (3.6%) | 1 (1.7%) | |